Adverum Biotechnologies, Inc.
adverum.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 12, 2025. Its latest SEC filing is a 15-12G from Dec 19, 2025.
10-Q for Q3 FY2025, filed Nov 12, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops ocular gene therapy candidates for patients with wet age-related macular degeneration and other ocular diseases.
10-K for FY2024, filed Apr 15, 2025Adverum is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. We…View ↗
How Did They Make Money?
So far, it has earned revenue from partner research, collaboration and licensing arrangements, not product sales. License deals can bring an upfront payment, payments when development milestones are reached, and royalties on licensed-product sales.
10-K for FY2024, filed Apr 15, 2025While we may in the future generate revenue from a variety of sources, including license fees, milestone, and research and development…View ↗
To date we have not generated any revenue from the sale of our products. We have generated revenue through research, collaboration and…View ↗
On January 25, 2021, the Company and Lexeo Therapeutics, Inc (“Lexeo”) entered into a License Agreement pursuant to which the Company…View ↗
Under the terms of the agreement, the Company is eligible to receive additional payments upon the achievement of certain milestones.…View ↗
$1M
-
10-K for FY2024, filed Apr 15, 2025
$1M ↗
Who Were Their Customers?
Strategic partners work directly with Adverum through license and research or collaboration agreements, including arrangements for gene-therapy rights and programs.
10-K for FY2024, filed Apr 15, 2025To date we have not generated any revenue from the sale of our products. We have generated revenue through research, collaboration and…View ↗
License and Collaboration AgreementsView ↗
In February 2014, we entered into an agreement with GenSight Biologics (“GenSight”), in which we granted GenSight a non-exclusive license…View ↗
In February 2023, we entered into an agreement with Ray Therapeutics (“Ray”), pursuant to which we granted Ray a non-exclusive license to…View ↗
In January 2021, we entered into an agreement with Lexeo Therapeutics (“Lexeo”), pursuant to which we granted Lexeo an exclusive license to…View ↗
Did Revenues Turn Into Profits?
No. It lost $130.9M in .
10-K for FY2024, filed Apr 15, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 12, 2025
−$47.7MView ↗
- ▲ +47% (Loss)
- vs −$32.4M in Q3 FY2024
-
Dec 9, 2025
Adverum became a wholly owned subsidiary
The company asked Nasdaq to suspend trading and delist its shares.
Sources
8-K, filed Dec 9, 2025
As described in the Introductory Note above, on December 9, 2025, Purchaser irrevocably accepted for payment all Shares validly tendered…View ↗
-
Oct 24, 2025
Agreed to a merger with Eli Lilly
The offer included $3.56 in cash per share plus a contingent value right for up to $8.91 per right.
Sources
8-K, filed Oct 24, 2025
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser will commence a tender offer (the…View ↗
Disease focus
The older report described gene therapy programs for ocular and rare diseases, including a blue cone monochromacy candidate; the latest describes Ixo-vec for wet AMD and early-stage programs for other ocular diseases.
10-K for FY2021, filed Mar 29, 2022 10-K for FY2024, filed Apr 15, 2025Adverum is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases. We…View ↗
Who Did They Compete With?
Competes with 4D Molecular Therapeutics, AbbVie, Bayer, Clearside Biomedical, EyePoint Pharmaceuticals, Kodiak Sciences, Novartis, Ocular Therapeutix, Opthea, Outlook Therapeutics, Regeneron, REGENXBIO, and Roche
10-K for FY2024, filed Apr 15, 2025There are several other companies in the U.S. or Europe with marketed products or products in development for the treatment of chronic…View ↗
Loading...
